Tarantino, Paolo http://orcid.org/0000-0001-8686-0228
Leone, Julieta
Vallejo, Carlos T.
Freedman, Rachel A.
Waks, Adrienne G.
Martínez-Sáez, Olga
Garrido-Castro, Ana http://orcid.org/0000-0002-5989-6636
Lynce, Filipa http://orcid.org/0000-0001-6615-7076
Tayob, Nabihah
Lin, Nancy U.
Tolaney, Sara M. http://orcid.org/0000-0002-5940-8671
Leone, Jose P. http://orcid.org/0000-0002-8537-652X
Article History
Received: 19 December 2023
Accepted: 22 March 2024
First Online: 4 April 2024
Competing interests
: P.T. reports serving as advisor/consultant for AstraZeneca, Daiichi-Sankyo, Gilead and Lilly. O.M.S. reports travel expenses and consulting fees from Roche and Reveal Genomics and speaker fees from Eisai, Daiichi and Novartis. OMS is a SEOM visiting fellow 2022. A.G.C. reports research funding (to the Institution) from AstraZeneca, Daiichi-Sankyo, Merck, Gilead Sciences, Zenith Epigenetics, Bristol-Myers Squibb, Novartis, Biovica International AB, and Foundation Medicine; and travel/accommodations (to scientific meeting) from Roche/Genentech. R.A.F. reports institutional funding from Puma Biotechnology. F.L. reports consulting/advisory role for AstraZeneca, Pfizer, Merck and Daiichi-Sankyo; and institutional research funding from Eisai, AstraZeneca, CytomX and Gilead Sciences. N.U.L. reports institutional research support from Genentech, Pfizer, Merck, Seattle Genetics (now Pfizer), Zion Pharmaceuticals (as part of GNE), Olema Pharmaceuticals, and AstraZeneca; consulting honoraria from Puma, Seattle Genetics, Daiichi-Sankyo, AstraZeneca, Olema Pharmaceuticals, Janssen, Blueprint Medicines, Stemline/Menarini, and Artera Inc., and Eisai; royalties from UpToDate (book); and travel support from Olema Pharmaceuticals. SMT reports a consulting or advisory role for Novartis, Pfizer, Merck, Eli Lilly, AstraZeneca, Genentech/Roche, Eisai, Sanofi, Bristol Myers Squibb, Seattle Genetics, CytomX Therapeutics, Daiichi-Sankyo, Gilead, OncXerna, Zymeworks, Zentalis, Blueprint Medicines, Reveal Genomics, ARC Therapeutics, Infinity Therapeutics, Sumitovant Biopharma, Umoja Biopharma, Artios Pharma, Menarini/Stemline, Aadi Biopharma, Bayer, Incyte Corp, Jazz Pharmaceuticals, Natera, Tango Therapeutics, Systimmune, eFFECTOR, and Hengrui USA. S.M.T. receives research funding from Genentech/Roche, Merck, Exelixis, Pfizer, Lilly, Novartis, Bristol Myers Squibb, Eisai, AstraZeneca, Gilead, NanoString Technologies, Seattle Genetics, and OncoPep, and receives travel support from Eli Lilly, Sanofi, Gilead, and Pfizer. J.P.L. reports research funding from Kazia Therapeutics and consulting from Minerva Biotechnologies. The remaining authors declare no conflicts of interest.